ProfileGDS5678 / 1460493_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 23% 23% 22% 22% 22% 29% 28% 22% 22% 22% 22% 22% 46% 22% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5682823
GSM967853U87-EV human glioblastoma xenograft - Control 22.5260223
GSM967854U87-EV human glioblastoma xenograft - Control 32.5269122
GSM967855U87-EV human glioblastoma xenograft - Control 42.4666122
GSM967856U87-EV human glioblastoma xenograft - Control 52.4604122
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7437329
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.681928
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.5048822
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.486422
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5151822
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5120922
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.491622
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0788646
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5158422